¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® º¸°í¼­ : ¿ëµµº°, ¼­ºñ½º À¯Çüº°, ¹Ì»ý¹°º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Microbiology CRO Services Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, Service Type, Microorganisms, End User, and Geography
»óǰÄÚµå : 1591412
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 227 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,186,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 8,967,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,748,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â 2023³â 55¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2031³â 115¾ï 1,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁö 9.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Ç×±ÕÁ¦ ÀÓ»ó ÆÄÀÌÇÁ¶óÀÎÀº 2021³â 80°³¿¡¼­ 2023³â 97°³·Î Áõ°¡Çß½À´Ï´Ù. ½É°¢ÇÑ °¨¿°¼º ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ »õ·Ó°í Çõ½ÅÀûÀÎ ¾à¹°ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ³Î¸® »ç¿ëµÇ¾î È¿°ú°¡ ¾ø¾îÁø ¾à¹°À» ´ëüÇÒ Çʿ䵵 ÀÖ½À´Ï´Ù. Ç×»ýÁ¦ ¹× ¼¼±Õ ¹é½ÅÀÇ ¿¬±¸°³¹ßÀ» À§Çؼ­´Â ÀüÀÓ»ó ¹× ÀÓ»ó½ÃÇè¿¡¼­ ´Ù¾çÇÑ ¹Ì»ý¹°ÇÐÀû ½ÃÇèÀÌ ÇÊ¿äÇϸç, Pacific Biolabs, SSI, Charles River Laboratories¿Í °°Àº ´Ù¾çÇÑ CRO°¡ ¼¼±Õ¼º »ý¹°Ã¼ ½ºÅ©¸®´× °Ë»ç, LAL, ¼¼±Õ¼º ³»µ¶¼ÒÀÇ ÀÓ»ó½ÃÇè ¹× ÀüÀÓ»ó ¾à¹°½ÃÇèÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

Ç×±ÕÁ¦ À¯È¿¼º ½ÃÇè, ¹ÙÀÌ¿À¹öµç ½ÃÇè, ¼Òµ¶Á¦ À¯È¿¼º ½ÃÇè, ¹«±Õ¼º ½ÃÇè, ±â»ýÃæ ½ÃÇè, ¼ºÀå ÃËÁø ½ÃÇè, Ç×±ÕÁ¦ °¨¼ö¼º ½ÃÇè, ¹Ì»ý¹° µ¿Á¤, µ¶¼º ½ÃÇèÀº ÀÓ»ó ¹× ÀüÀÓ»ó ÀǾàǰ °³¹ß ¿¬±¸¿¡ ÇÊ¿äÇÑ Áß¿äÇÑ ¹Ì»ý¹° ½ÃÇè ¹æ¹ý Áß ÀϺÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹æ¹ýÀº ¹Ì±¹ ½ÄǰÀǾ౹(FDA), À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦ ±â°ü¿¡¼­ ¹Ì»ý¹° ¿À¿°ÀÇ °ËÃâ ¹× Á¤·®È­, ÀÇ·á±â±â ¸ê±Õ, ÀüÀÓ»ó½ÃÇè µîÀ» À§ÇØ ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¹öµç °Ë»ç(ÃÑ »ýÁ¸¼ö °Ë»ç)´Â Á¦Ç° ³» ¹Ì»ý¹° ¿À¿° ¼öÁØÀ» ÃøÁ¤ÇÕ´Ï´Ù. ¹Ì»ý¹° ¿À¿°Àº ¿ø·á, Á÷¿ø, Á¦Á¶ ȯ°æ¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. STERIS´Â ÀÇ·á±â±â, ÀǾàǰ, µ¿¹°Á¶Á÷, È­Àåǰ¿¡ ´ëÇÑ ¹ÙÀÌ¿À¹öµç °Ë»ç ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ¼±µµÀûÀÎ ±â¾÷ Áß ÇϳªÀÔ´Ï´Ù. Á¦¾àȸ»ç´Â CRO¿¡ µ¶¼º½ÃÇèÀ» À§Å¹ÇÏ¿© ÀǾàǰ °³¹ßÀ» °³¼±ÇÒ ¼ö ÀÖÀ¸¸ç, CRO´Â ½ÃÇèÀ» È¿À²ÀûÀ¸·Î ¼öÇàÇÒ ¼ö ÀÖ´Â Àü¹® Áö½Ä°ú ÀÚ¿øÀ» º¸À¯Çϰí Àֱ⠶§¹®¿¡ °³¹ßÀÚ´Â ´Ù¸¥ Ãø¸é¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. µ¶¼ºÇÐ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ CRO·Î´Â Altasciences, AmplifyBio µîÀÌ ÀÖ½À´Ï´Ù.

¿¬±¸°³¹ß ÅõÀÚ ±ÞÁõÀ¸·Î ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º Ȱ¼ºÈ­

¿¬±¸´Â Á¦¾à, ¹ÙÀÌ¿ÀÁ¦¾à, ÀÇ·á±â±â »ê¾÷ µî¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇϰí ÇʼöÀûÀÎ ¿ä¼Ò·Î, ÀÇ·á ¹× »ó¾÷Àû ÀáÀç·ÂÀÌ Å« ´Ù¾çÇÑ Ä¡·á ¿ëµµ¸¦ À§ÇÑ »õ·Î¿î ¼Ö·ç¼ÇÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. Á¦¾à »ê¾÷Àº ¼¼°è¿¡¼­ °¡Àå ¿¬±¸°³¹ß Áý¾àÀûÀÎ »ê¾÷ÀÔ´Ï´Ù. ȯÀÚµéÀÇ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ´õ ³ôÀº È¿´É°ú È¿À²¼ºÀ» ´Þ¼ºÇϱâ À§ÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ÀǾàǰ ºñ¿ëÀº Á¦¾àȸ»çÀÇ °¡Àå Å« °ü½É»çÀ̸ç, ºñ¿ë ¸ñÇ¥¸¦ ´Þ¼ºÇϱâ À§ÇØ R&D Ȱµ¿¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Áö³­ 10³â°£ ¸Å³â ½ÂÀεǴ ½Å¾àÀÇ ¼öµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº 2022³â¿¡ ¿¬°£ 37°³ÀÇ ½Å¾àÀ» ½ÂÀÎÇß½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¹Ì±¹Àº Áö³­ 10³â°£ Àü ¼¼°è ½Å¾àÀÇ 50% ÀÌ»óÀ» »ý»êÇÑ ¿¬±¸°³¹ß ÅõÀÚÀÇ ¼±µÎÁÖÀÚÀÔ´Ï´Ù. À¯·´Á¦¾àÇùȸ(EFPIA)¿¡ µû¸£¸é 2021³â ºÏ¹Ì´Â Àü ¼¼°è ÀǾàǰ ¸ÅÃâÀÇ 49.1%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹Àº 2016³âºÎÅÍ 2021³â±îÁö Ãâ½ÃµÈ ½Å¾à ¸ÅÃâÀÇ 64.4%¸¦ Â÷ÁöÇÕ´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ ±â¹Ý ÀλçÀÌÆ®

Á¾¾çÇÐ, Èñ±ÍÁúȯ, ¸é¿ªÇÐ, ¸ÂÃãÀÇ·á µî Æ´»õ Ä¡·á ºÐ¾ßÀÇ Àü¹® Áö½Ä¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷µéÀº ¿¬±¸°³¹ßÀ» Áö¿øÇϱâ À§ÇØ Æ¯Á¤ ºÐ¾ß¿¡ ´ëÇÑ Áö½Ä°ú °æÇèÀ» °®Ãá CRO¸¦ ã°í ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº º¸´Ù ¹ÎøÇϰí Çõ½ÅÀûÀÎ ºñÁî´Ï½º ¸ðµ¨À» äÅÃÇϱ⠽ÃÀÛÇϸ鼭 ÀÓ»ó °³¹ß ¿ä±¸»çÇ׿¡ ´ëÇØ Áß¼ÒÇü CRO¸¦ ¼±È£Çϱ⠽ÃÀÛÇß½À´Ï´Ù. ¿¬±¸ Ȱµ¿À» ¾Æ¿ô¼Ò½ÌÇÔÀ¸·Î½á ±â¾÷Àº ¿¬±¸ ÀÎÇÁ¶ó¿Í Àη¿¡ ÅõÀÚÇÏÁö ¾Ê°íµµ ½Ã°£°ú ºñ¿ëÀ» Àý¾àÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æ¿ì¿¡ µû¶ó¼­´Â CRO°¡ Çõ½ÅÀÇ ÁÖµµ±ÇÀ» Áã°í È­ÇÐÀû ¶Ç´Â »ý¹°ÇÐÀû ¹æ¹ýÀ¸·Î Áúº´¿¡ ´ëÇÑ ÁøÀÔÁ¡À» Á¶±â¿¡ È®¸³Çϰí Á¦¾àȸ»ç¿ÍÀÇ Á¦ÈÞ¸¦ ¸ð»öÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. 2023³â 9¿ù, ¼­¹ö ÇコÄɾî´Â ÀÓ»ó½ÃÇèÀ» À§ÇÑ ¹ÙÀÌ¿À ºÐ¼® ¿ª·®À» °­È­Çϱâ À§ÇØ CIRION BioPharma Research¸¦ ÀμöÇß½À´Ï´Ù. À̸¦ ÅëÇØ ¾àµ¿ÇÐ/¾à·ÂÇÐ(PKPD) ¹× ¸é¿ª¿ø¼º ½ÃÇè¿¡ ´ëÇÑ Àü¹®¼ºÀ» °­È­ÇÏ°í ºÏ¹Ì¿¡¼­ÀÇ ÀÔÁö¸¦ È®´ëÇß½À´Ï´Ù.

À¯·´Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ, ¿µ±¹Á¦¾à»ê¾÷Çùȸ, ½ÄǰÀǾàǰ¾ÈÀüû, ¿µ±¹Á¦¾à»ê¾÷Çùȸ µîÀº ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå º¸°í¼­¸¦ ÀÛ¼ºÇÒ ¶§ Âü°íÇÑ 1Â÷ ¹× 2Â÷ Á¤º¸¿øÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå »óȲ

Á¦5Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå ºÐ¼® - ¿ëµµº°

Á¦8Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå ºÐ¼® - ¼­ºñ½º À¯Çüº°

Á¦9Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå ºÐ¼® - ¹Ì»ý¹°º°

Á¦10Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå ºÐ¼® - ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå - Áö¿ªº° ºÐ¼®

Á¦12Àå ¹Ì»ý¹°ÇÐ CRO ¼­ºñ½º ½ÃÀå - ¾÷°è »óȲ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The microbiology CRO services market size is expected to grow from US$ 11.51 billion by 2031 from US$ 5.52 billion in 2023. The market is expected to register a CAGR of 9.6% during 2023-2031.

According to the World Health Organization (WHO), the clinical pipeline of antibacterial agents saw an increase from 80 in 2021 to 97 in 2023. There is a growing need for new, innovative agents to treat serious infections as well as replace those that are becoming ineffective due to widespread use. The research and development of antibiotics and bacterial vaccines require various microbiological tests during their preclinical and clinical studies. Various CROs such as Pacific Biolabs, SSI, and Charles River Laboratories offer screening tests for bacterial organisms, LAL, and bacterial endotoxins testing clinical and preclinical drug testing.

Antimicrobial effectiveness, bioburden testing, disinfectant efficacy testing, sterility testing, parasite testing, growth promotion testing, antimicrobial susceptibility testing, microbial identification, and toxicological testing are a few of the crucial microbial testing methods required for clinical and preclinical drug development studies. These methods are recommended by regulatory bodies such as the Food and Drug Association (FDA) and the European Medicines Agency (EMA) for the detection and quantification of microbial contamination, medical device sterilization, and preclinical studies. Bioburden testing, or total viable count testing, measures microbial contamination levels in a product. It can come from raw materials, the workforce, or the manufacturing environment. Due to multiple sources of contamination, regular testing is advisable. STERIS is one of the leading bioburden testing services for medical devices, pharmaceuticals, animal tissue, and cosmetics. Pharmaceutical companies can improve drug development by outsourcing toxicological testing to CROs. CROs have the expertise and resources to efficiently conduct studies, allowing developers to focus on other aspects. Notable CROs offering toxicological services include Altasciences and AmplifyBio.

Surging Research and Development Investments Propels Microbiology CRO Services

Research is a significant and essential part of the pharmaceutical, biopharmaceutical, and medical device industries, among others, which enables them to develop new solutions for various therapeutic applications with significant medical and commercial potential. The pharmaceutical industry is one of the most research and development-intensive industries in the world. Efforts are being made to achieve greater effectiveness and efficiency in fulfilling patients' needs. The cost of medicines has been a prime concern for pharmaceutical companies as they bank on their research and development activities to achieve intended cost targets. Over the last decade, the number of new drugs approved yearly has also increased. The Food and Drug Administration (FDA) approved 37 new drugs annually in 2022. Globally, the US is a leading country in terms of research and development investments, and the country produced over 50% of the world's new molecules in the past decade. As per the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2021, North America accounted for 49.1% of global pharmaceutical sales. The US accounted for 64.4% of sales of new medicines launched during 2016-2021.

End User-Based Insights

The demand for specialized expertise in niche therapeutic areas such as oncology, rare diseases, immunology, and personalized medicine is growing. Pharmaceutical and biotechnology companies seek CROs showcasing knowledge and experience in specific areas to support their research and development efforts. These companies have started to prefer small to medium-sized CROs for their clinical development requirements as they are beginning to adopt a more agile and innovative business model. By outsourcing research activities, companies can save time and costs by not investing in research infrastructure and workforce.

In a few cases, CROs may even take the lead in innovation by establishing early chemistry and biology entry points into diseases and then seek collaboration with pharmaceutical companies. In September 2023, Cerba HealthCare acquired CIRION BioPharma Research to enhance its bioanalytical capabilities for clinical trials. This strengthened the company's expertise in Pharmacokinetic/Pharmacodynamic (PKPD) and Immunogenicity testing and expanded its presence in North America.

The European Center for Disease Prevention and Control, Association of the British Pharmaceutical Industry, Food and Drug Administration, and Association of the British Pharmaceutical Industry are among the primary and secondary sources referred to while preparing the Microbiology CRO Services market report.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Microbiology CRO Services Market Landscape

5. Microbiology CRO services market - Key Market Dynamics

6. Microbiology CRO services market - Global Market Analysis

7. Microbiology CRO Services Market Analysis - by Application

8. Microbiology CRO Services Market Analysis - by Service Type

9. Microbiology CRO services market Analysis - by Microorganisms

10. Microbiology CRO services market Analysis - by End User

11. Microbiology CRO services market - Geographical Analysis

12. Microbiology CRO Services Market - Industry Landscape

13. Company Profiles

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â